MeSH D020256 - choroidal neovascularization
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009389:Pathologic neovascularization
0 Companies
0 Drugs
Success rate
D015862:Choroid diseases
0 Companies
0 Drugs
Success rate
D020256: 
Choroidal neovascularization
$
Success rate
D000092342:Polypoidal choroidal vasculopathy
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Bausch Health CompaniesVerteporfin Visudyne  2000-04-12   
CHEPLAPHARM ArzneimittelVerteporfin Visudyne  2000-07-27   
NovartisRanibizumab Lucentis  2007-01-22 $1,722 M Q2/21-Q2/24 
Clinical Trials
Historical Success Rate
Phase 1
86%
12/14
Phase 2
41%
7/17
Phase 3
36%
4/11
Approved: 1Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use